CBL-514 Injection

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Subcutaneous Fat

Conditions

Subcutaneous Fat

Trial Timeline

May 30, 2023 → May 20, 2024

NCT ID

NCT05736107

About CBL-514 Injection

CBL-514 Injection is a phase 2 stage product being developed by Caliway Biopharmaceuticals for Subcutaneous Fat. The current trial status is completed. This product is registered under clinical trial identifier NCT05736107. Target conditions include Subcutaneous Fat.

What happened to similar drugs?

0 of 3 similar drugs in Subcutaneous Fat were approved

Approved (0) Terminated (0) Active (3)

🔄TR-701 FA + LinezolidMerckPhase 3

🔄CBL-514 InjectionCaliway BiopharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07140939	Phase 3	Recruiting	Sep 1, 2025	Sep 1, 2026	Subcutaneous Fat
NCT05736107	Phase 2	Completed	May 30, 2023	May 20, 2024	Subcutaneous Fat
NCT05836779	Phase 2	Completed	May 10, 2023	Jan 5, 2024	Cellulite
NCT04897412	Phase 2	Completed	Feb 14, 2022	Mar 22, 2023	Subcutaneous Fat

Competing Products

9 competing products in Subcutaneous Fat

See all competitors

Product	Company	Stage	Hype Score
TR-701 FA + Linezolid	Merck	Phase 3	40
TR-701 FA + Linezolid	Merck	Phase 3	40
CBL-514	Caliway Biopharmaceuticals	Phase 2	35
CBL-514 Injection	Caliway Biopharmaceuticals	Phase 2	35
CBL-514, placebo + CBL-514, placebo + CBL-514	Caliway Biopharmaceuticals	Phase 1	29
CBL-514 Injection	Caliway Biopharmaceuticals	Phase 3	47
CBL-514	Caliway Biopharmaceuticals	Phase 2	35
CBL-514	Caliway Biopharmaceuticals	Phase 2	35
CBL-514 injection + CBL-A1 Injection + CBL-A2 Injection + 0.9% Sodium Chloride	Caliway Biopharmaceuticals	Phase 2	35